TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Efficacy and the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects With Crohn's Disease Who Have Demonstrated a Clinical Response in the M06-806 Study
Brief Summary: This was a multicenter, open-label study to evaluate the human monoclonal anti-TNF-α antibody adalimumab as an effective therapy for maintaining clinical response in pediatric participants with Crohn's disease (CD) and to gather long-term safety and tolerability data in this population. Participants were allowed to enroll in the study if they participated in and successfully completed Study M06-806 (NCT00409682) through Week 52.


Options:
A: Arm Label: DB Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo eow; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: OL Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): DB Adalimumab 40 mg eow, OL Adalimumab 40 mg eow | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo eow
B: Arm Label: Any adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Any adalimumab
C: Arm Label: Adalimumab 160 mg/80 mg; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 80 mg/40 mg; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 160 mg/80 mg | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 80 mg/40 mg | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Open-label adalimumab (Week 0 to Week 4); Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52); Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52); Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Open-label adalimumab (Week 0 to Week 4) | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52) | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Utility of Insulin Glargine (Lantus) Compared to NPH in Ethnic Minority Type 2 Diabetic Subjects Starting Insulin Therapy
Brief Summary: To compare the efficacy and safety of once-nightly insulin glargine versus a single morning injection of glargine or once-nightly NPH insulin in ethnic minority type 2 diabetic patients inadequately controlled on combination oral agents.


Options:
A: Arm Label: neutral protamine insulin, metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin detemir | Arm Label: insulin detemir, metformin; Type: EXPERIMENTAL; Interventions: Drug: neutral protamine insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): neutral protamine insulin, metformin | Intervention Type: DRUG; Name: neutral protamine insulin; Assigned to Arm(s): insulin detemir, metformin
B: Arm Label: Insulin glargine injected at bedtime; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine at bedtime instead of NPH | Arm Label: NPH insulin injected twice-daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: NPH twice-daily | Intervention Type: DRUG; Name: Insulin glargine at bedtime instead of NPH; Assigned to Arm(s): Insulin glargine injected at bedtime | Intervention Type: DRUG; Name: NPH twice-daily; Assigned to Arm(s): NPH insulin injected twice-daily
C: Arm Label: 1 - Insulin glargine QHS; Type: EXPERIMENTAL; Interventions: Drug: 1- Insulin glargine QHS | Arm Label: 2 - Insulin glargine QAM; Type: EXPERIMENTAL; Interventions: Drug: 2 - Insulin glargine QAM | Arm Label: 3 - NPH Insulin QHS; Type: ACTIVE_COMPARATOR; Interventions: Drug: 3 - NPH insulin QHS | Intervention Type: DRUG; Name: 1- Insulin glargine QHS; Assigned to Arm(s): 1 - Insulin glargine QHS | Intervention Type: DRUG; Name: 2 - Insulin glargine QAM; Assigned to Arm(s): 2 - Insulin glargine QAM | Intervention Type: DRUG; Name: 3 - NPH insulin QHS; Assigned to Arm(s): 3 - NPH Insulin QHS
D: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (U300) | Arm Label: "Standard of care" commercially available basal insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine (U100), Drug: NPH insulin, Drug: insulin detemir, Drug: insulin degludec | Intervention Type: DRUG; Name: insulin glargine (U300); Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: insulin glargine (U100); Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): "Standard of care" commercially available basal insulin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Utility of Insulin Glargine (Lantus) Compared to NPH in Ethnic Minority Type 2 Diabetic Subjects Starting Insulin Therapy
Brief Summary: To compare the efficacy and safety of once-nightly insulin glargine versus a single morning injection of glargine or once-nightly NPH insulin in ethnic minority type 2 diabetic patients inadequately controlled on combination oral agents.


Options:
A: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (U300) | Arm Label: "Standard of care" commercially available basal insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine (U100), Drug: NPH insulin, Drug: insulin detemir, Drug: insulin degludec | Intervention Type: DRUG; Name: insulin glargine (U300); Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: insulin glargine (U100); Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): "Standard of care" commercially available basal insulin
B: Arm Label: 1 - Insulin glargine QHS; Type: EXPERIMENTAL; Interventions: Drug: 1- Insulin glargine QHS | Arm Label: 2 - Insulin glargine QAM; Type: EXPERIMENTAL; Interventions: Drug: 2 - Insulin glargine QAM | Arm Label: 3 - NPH Insulin QHS; Type: ACTIVE_COMPARATOR; Interventions: Drug: 3 - NPH insulin QHS | Intervention Type: DRUG; Name: 1- Insulin glargine QHS; Assigned to Arm(s): 1 - Insulin glargine QHS | Intervention Type: DRUG; Name: 2 - Insulin glargine QAM; Assigned to Arm(s): 2 - Insulin glargine QAM | Intervention Type: DRUG; Name: 3 - NPH insulin QHS; Assigned to Arm(s): 3 - NPH Insulin QHS
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin | Intervention Type: DRUG; Name: Insulin Glargine (HOE901)/NPH Insulin; Assigned to Arm(s): 1, 2
D: Intervention Type: DRUG; Name: Metformin on top of intensive insulin therapy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Patient Outcomes in End-of-Life Care Provided by Physicians and Nurses
Brief Summary: This research study is a randomized trial to evaluate a training program that is designed to improve the communication skills of clinicians. The training program focuses on care for patients with serious illnesses and their family members, and assesses effectiveness using patient and family outcomes. The long term goal of this research is to improve communication skills of doctors and nurses, thereby improving patient and family outcomes.


Options:
A: Arm Label: Intervention Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Training Program Intervention | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training Program Intervention; Assigned to Arm(s): Intervention Arm
B: Arm Label: video decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: video decision aid | Arm Label: Usual Care -- Verbal Description Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: video decision aid; Assigned to Arm(s): video decision aid
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ACTIVE; Type: EXPERIMENTAL; Interventions: Behavioral: ACTIVE | Intervention Type: BEHAVIORAL; Name: ACTIVE; Assigned to Arm(s): ACTIVE
D: Arm Label: Usual informed consent; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual, standard-of-care informed consent for chemotherapy | Arm Label: Investigational informed consent; Type: EXPERIMENTAL; Interventions: Other: Investigational informed consent for chemotherapy | Intervention Type: OTHER; Name: Investigational informed consent for chemotherapy; Assigned to Arm(s): Investigational informed consent | Intervention Type: OTHER; Name: Usual, standard-of-care informed consent for chemotherapy; Assigned to Arm(s): Usual informed consent

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Patient Outcomes in End-of-Life Care Provided by Physicians and Nurses
Brief Summary: This research study is a randomized trial to evaluate a training program that is designed to improve the communication skills of clinicians. The training program focuses on care for patients with serious illnesses and their family members, and assesses effectiveness using patient and family outcomes. The long term goal of this research is to improve communication skills of doctors and nurses, thereby improving patient and family outcomes.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Communication training and coaching | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Communication training and coaching; Assigned to Arm(s): Intervention
B: Arm Label: Nueva Vida Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nueva Vida Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nueva Vida Intervention; Assigned to Arm(s): Nueva Vida Intervention
C: Arm Label: Intervention Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Training Program Intervention | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training Program Intervention; Assigned to Arm(s): Intervention Arm
D: Arm Label: communication lecture; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: communication lecture | Arm Label: lecture plus CD-ROM; Type: EXPERIMENTAL; Interventions: Behavioral: lecture plus CD-ROM | Intervention Type: BEHAVIORAL; Name: communication lecture; Assigned to Arm(s): communication lecture | Intervention Type: BEHAVIORAL; Name: lecture plus CD-ROM; Assigned to Arm(s): lecture plus CD-ROM

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Utility of Insulin Glargine (Lantus) Compared to NPH in Ethnic Minority Type 2 Diabetic Subjects on Combination Insulin-Oral Agent Therapy
Brief Summary: To compare the efficacy and safety of once-nightly insulin glargine versus twice-daily NPH insulin in ethnic minority type 2 diabetic patients inadequately treated with once-nightly NPH insulin alone.


Options:
A: Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): N/A
B: Arm Label: Insulin glargine injected at bedtime; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine at bedtime instead of NPH | Arm Label: NPH insulin injected twice-daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: NPH twice-daily | Intervention Type: DRUG; Name: Insulin glargine at bedtime instead of NPH; Assigned to Arm(s): Insulin glargine injected at bedtime | Intervention Type: DRUG; Name: NPH twice-daily; Assigned to Arm(s): NPH insulin injected twice-daily
C: Arm Label: 1. Insulatard; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulatard | Arm Label: 2. Detemir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Detemir | Intervention Type: DRUG; Name: Insulatard; Assigned to Arm(s): 1. Insulatard | Intervention Type: DRUG; Name: Detemir; Assigned to Arm(s): 2. Detemir
D: Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-masked, Multicenter, Laser-controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Mono-therapy in Patients With Visual Impairment Due to Diabetic Macular Edema
Brief Summary: CRFB002D2301: The core study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or mono-therapy in patients with visual impairment due to diabetic macular edema.

CRFB002D2301E1: A 24 month open-label extension study for participants who completed the 12 month core study evaluated the long-term safety and efficacy of ranibizumab (0.5 mg) as symptomatic treatment for visual impairment due to diabetic macular edema.


Options:
A: Arm Label: Sham Control; Type: SHAM_COMPARATOR; Interventions: Drug: Standard of Care | Arm Label: Macugen; Type: EXPERIMENTAL; Interventions: Drug: Macugen | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Sham Control | Intervention Type: DRUG; Name: Macugen; Assigned to Arm(s): Macugen
B: Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
D: Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: triamcinolone acetonide; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-masked, Multicenter, Laser-controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Mono-therapy in Patients With Visual Impairment Due to Diabetic Macular Edema
Brief Summary: CRFB002D2301: The core study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or mono-therapy in patients with visual impairment due to diabetic macular edema.

CRFB002D2301E1: A 24 month open-label extension study for participants who completed the 12 month core study evaluated the long-term safety and efficacy of ranibizumab (0.5 mg) as symptomatic treatment for visual impairment due to diabetic macular edema.


Options:
A: Arm Label: Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser photocoagulation | Arm Label: Laser with Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser photocoagulation | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser with Ranibizumab, Ranibizumab | Intervention Type: PROCEDURE; Name: Laser photocoagulation; Assigned to Arm(s): Laser, Laser with Ranibizumab
B: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg
C: Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab
D: Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-masked, Multicenter, Laser-controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Mono-therapy in Patients With Visual Impairment Due to Diabetic Macular Edema
Brief Summary: CRFB002D2301: The core study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or mono-therapy in patients with visual impairment due to diabetic macular edema.

CRFB002D2301E1: A 24 month open-label extension study for participants who completed the 12 month core study evaluated the long-term safety and efficacy of ranibizumab (0.5 mg) as symptomatic treatment for visual impairment due to diabetic macular edema.


Options:
A: Intervention Type: PROCEDURE; Name: Eccentric Viewing Training for Reading; Assigned to Arm(s): N/A
B: Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Other: Interdisciplinary Low Vision Service | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Basic Low Vision Service | Intervention Type: OTHER; Name: Interdisciplinary Low Vision Service; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Basic Low Vision Service; Assigned to Arm(s): Arm 2
D: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg

Answer: B